MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.09
-0.22
-1.08%
After Hours: 20.09 0 0.00% 19:31 07/02 EDT
OPEN
20.43
PREV CLOSE
20.31
HIGH
20.76
LOW
19.75
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
22.28
52 WEEK LOW
4.950
MARKET CAP
2.41B
P/E (TTM)
-10.0155
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TGTX stock price target is 39.33 with a high estimate of 65.00 and a low estimate of 23.00.

EPS

TGTX News

More
TG Therapeutics Highlights Presentation Of Preclinical Data For TG-1701 BTK Inhibitor At AACR Meeting
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual
Benzinga · 06/22 13:09
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual meeting, being held virtually. Importantly, we are pleas
GlobeNewswire · 06/22 13:00
bluebird On The Go, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/18 01:02
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
GlobeNewswire · 06/17 12:00
TG Therapeutics finishes U.S. application for umbralisib for certain B-cell blood cancers
Seeking Alpha - Article · 06/17 11:18
TG Therapeutics Completes Rolling Submission Of New Drug Application To FDA For Umbralisib As A Treatment For Patients With Previously Treated Marginal Zone Lymphoma Or Follicular Lymphoma
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the completion of the
Benzinga · 06/17 11:02
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
GlobeNewswire · 06/16 12:00
TG Therapeutics: Assessing The Commercialization Case
Seeking Alpha - Article · 06/15 15:48

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About TGTX

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
More

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.